Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia

BMC Urology

Research Article

Jameel Nazir¹  Zalmai Hakimi²  Cristina Ivanescu³  Lars Heemstra³  Anke van Engen³ 

[1] Astellas Pharma Europe Ltd, Chertsey, UK;Astellas Pharma Global Development, Leiden, Netherlands;Quintiles Consulting, Hoofddorp, Netherlands;

关键词: Benign prostatic hyperplasia;    Cost-effectiveness;    Fixed-dose combination;    Incremental cost-effectiveness ratio;    Lower urinary tract symptoms;    Quality adjusted life years;    Solifenacin;    Tamsulosin;    Tolterodine;   

DOI  :  10.1186/s12894-015-0031-8

 received in 2014-11-14, accepted in 2015-04-16,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundStorage symptoms, associated with benign prostatic hyperplasia (BPH), often co-exist with voiding symptoms in men with lower urinary tract symptoms (LUTS). Storage symptoms are likely to be most bothersome, and may not be adequately resolved by treatment with α-blocker or antimuscarinic monotherapy. A recent randomised controlled phase 3 trial (NEPTUNE) demonstrated that a fixed-dose combination (FDC) of solifenacin 6 mg plus an oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg) improved storage symptoms, as well as quality of life, compared with TOCAS alone in men with moderate-to-severe storage symptoms and voiding symptoms. This analysis aimed to assess the cost-effectiveness of a FDC tablet of solifenacin 6 mg plus TOCAS relative to tolterodine plus tamsulosin given concomitantly, from the perspective of the UK National Health Service (NHS).MethodsA Markov model was developed for men aged ≥45 years with LUTS/BPH who have moderate-to-severe storage symptoms and voiding symptoms. The model calculated cost-effectiveness over an analytical time horizon of 1 year and estimated total treatment costs, quality adjusted life years (QALYs) and incremental cost-effectiveness ratio.ResultsThe FDC tablet of solifenacin 6 mg plus TOCAS was associated with lower total annual costs (£860 versus £959) and increased QALYs (0.839 versus 0.836), and was therefore dominant compared with tolterodine plus tamsulosin. Time horizon, discontinuation or withdrawal rates, drug cost and utility values were the main drivers of cost-effectiveness. The probability that the FDC tablet of solifenacin 6 mg plus TOCAS is cost-effective was 100% versus tolterodine plus tamsulosin, at a willingness-to-pay threshold of £20,000/QALY gained.ConclusionsThe FDC tablet of solifenacin 6 mg plus TOCAS provides important clinical benefits and is a cost-effective treatment strategy in the UK NHS compared with tolterodine plus tamsulosin for men with both storage and voiding LUTS/BPH.

【 授权许可】

CC BY   
© Nazir et al. 2015